Insulin Secretion in the Obese (ob/ob) Mouse: The Effect of Oxytetracycline on Insulin Release
- Department of Biochemistry, University of Ottawa, and the Eleanor M. Patterson Department of Laboratory Medicine and Research, Children's Hospital of Eastern Ontario Ottawa, Canada
- Address reprint requests to Dr. Nicole Bégin-Heick, Department of Biochemistry, Health Sciences Center, University of Ottawa, 451 Smyth Road, Ottawa, K1H 8M5, Ontario, Canada.
The effect of oxytetracycline (OTC) pretreatment on the response of the ob /ob mouse to insulin secretagogues in vivo and in vitro was investigated. With glucose loading in vivo, the peak glucose was twofold greater and the insulin levels threefold greater in obese than in lean mice. After OTC treatment, there was no significant difference in insulin levels between lean and obese mice although the peak glucose level was still 1.5 times as high. Glucagon increased plasma glucose 2.5-fold and plasma insulin 20-fold in the obese as compared with lean mice. After OTC treatment, the glycemie response of the obese was indistinguishable from that of the lean control. The insulin levels, while higher than those of lean mice, were only 25% of those found in the untreated obese. Aminophylline produced an 8- and a 20-fold increase in peak glucose and insulin levels, respectively, as compared with lean mice. In the OTC-treated obese mice, the injection of aminophylline produced a slower rise in plasma glucose than in the obese controls, but the levels were not significantly different from those of the untreated obese mice at 90 min. On the other hand, the insulin levels attained a plateau at a value which was one-fifth that found in the control obese group. In vitro, isolated islets from obese mice showed an exaggerated response to the secretagogues. Pretreatment with OTC attenuated this response. The fraction of insulin released at 10 mM glucose was less than one-fourth that in the obese controls. With glucagon added, the response was only one-eighth, and with aminophylline, one-half as great in the OTC-treated than in the obese control. The effects of OTC cannot be attributed to the effects of the drug on food consumption, since obese mice food restricted to the intake of the OTC-treated obese mice showed either no improvement or much smaller Changes.
- Received November 1, 1982.
- Revision received March 28, 1983.
- Copyright © 1983 by the American Diabetes Association